Outcome MeasurePersonality / Psychological

DES-II

Dissociative Experiences Scale-II

2 Papers in Blossom

About This Instrument

The Dissociative Experiences Scale-II (DES-II) is a 28-item self-report questionnaire measuring the frequency of dissociative experiences such as absorption, depersonalization, derealization, and amnesia. Respondents indicate the percentage of time (0–100%) they experience each item, and the overall score is the mean across all items. Developed by Eve Bernstein Carlson and Frank Putnam, the DES-II is the most widely used screening instrument for dissociative disorders. A mean score above 30 is generally considered indicative of a dissociative disorder. In psychedelic research, the DES-II is used to screen participants (high dissociation often being exclusionary) and to monitor dissociative experiences during or after psychedelic sessions. The scale has good test–retest reliability (r ≈ 0.79–0.84) and high internal consistency (α ≈ 0.93).

Clinical Thresholds

0100
Normal
Score 010
Mild
Score 1120
Moderate
Score 2130
Clinical
Score 31100

Outcome Data Across Studies

Reported results for DES-II across 2 studies with quantitative data.

Outcome data across 8 study arm–timepoint observations
SD
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial
2018Secondary
MDMA 40 mg(active_comparator)0614.46.5
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial
2018Secondary
MDMA 40 mg(active_comparator)28614.24.4
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial
2018Secondary
MDMA 40 mg(active_comparator)286-0.2Δ6.9
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial
2018Secondary
MDMA 40 mg(active_comparator)6057.23.7
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial
2018Secondary
MDMA 40 mg(active_comparator)6056.64.6
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial
2018Secondary
MDMA 40 mg(active_comparator)365235.55.2
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
2018Secondary
Full dose(experimental)0333.0
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial
2018Secondary
Full dose(experimental)60322.0

Papers Using DES-II

Quick Facts

Full Name
Dissociative Experiences Scale-II
Domain
Personality / Psychological
Papers Indexed
2
Score Range
0100
Interpretation
Lower = better
Unit
percentage
All Measures